AccScience Publishing / TD / Volume 2 / Issue 2 / DOI: 10.36922/td.0436
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

An evidence-based review on bexarotene

Ayushi Mahajan1 Lovepreet Singh1 Gurjeet Singh1 Ravi Kumar Dhawan1 Manjeet Kaur1 Pritpal Kaur Malhi1 Komal Thakur1 Lakhvir Kaur1*
Show Less
1 Department of Pharmaceutics, Khalsa College of Pharmacy, Amritsar, Punjab, India
Tumor Discovery 2023, 2(2), 0436
Submitted: 13 May 2023 | Accepted: 18 July 2023 | Published: 3 August 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Bexarotene is a selective retinoid X receptor agonist of utmost clinical importance. The United States Food and Drug Administration has approved this drug for its effects on cutaneous T-cell lymphoma. Bexarotene has shown great potential, demonstrating enhanced therapeutic activity against a plethora of tumor types, both as a single agent and as an adjuvant with other targeted agents. Despite its potential, bexarotene has turned out to be a nostrum, and formulation-related studies that explore its use have not received much emphasis. Poor aqueous solubility and low bioavailability are challenges in developing an appropriate formulation of this drug. In this review, we aim to provide insights into recent research conducted on formulation development, recent pharmacological findings, patents, and future research requisites of bexarotene, based on the literature gathered from authentic web resources and research articles. Bexarotene is a diamond in the rough, as many researchers have not yet recognized its multipotentiality. The incorporation of bexarotene into nanoformulations can surmount the current drawbacks and efficiently enhance its anticancer activity. In conclusion, this drug is a potentially effective and broad-spectrum anticancer drug for treating malignancies; therefore, extensive research is required to confirm its potential.

Cutaneous T-cell lymphoma
Anticancer drug
Retinoid X receptor
  1. Li L, Liu Y, Wang J, et al., 2014, Preparation, in vitro and in vivo evaluation of Bexarotene nanocrystals with surface modification by folate-chitosan conjugates. J Drug Deliv, 23(1): 79–87.


  1. Zhang C, Hazarika P, Ni X, et al., 2002, Induction of apoptosis by Bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res, 8(5): 1234–1240.


  1. Lowe MN, Plosker GL, 2000, Bexarotene. Am J Clin Dermatol, 1(4): 245–250.


  1. Fenaux P, Chomienne C, Degos L, 2001, All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol, 38(1): 13–25.


  1. Quéreux G, Saint-Jean M, Peuvrel L, et al., 2013, Bexarotene in cutaneous T-cell lymphoma: Third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother, 14(13): 1711–1721.


  1. Chen L, Wang Y, Zhang J, et al., 2014, Bexarotenenanocrystal- Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm, 87(1): 160–169.


  1. National Center for Biotechnology Information, 2023. Available from: compound/Bexarotene [Last accessed on 2023 Aug 01].


  1. Drug Future, 2023. Available from: https://www.drugfuture. com/chemdata/Bexarotene.html [Last accessed on 2023 Jun 30].


  1. Miller VA, Benedetti FM, Rigas JR, et al., 1997, Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol, 15(2): 790–795.


  1. Wayne RB, 1994, The retinoids: Biology, chemistry and medicine. J Am Coll Nutr, 13(6): 675–676.


  1. Chambon P, 1996, A decade of molecular biology of retinoic acid receptors. FASEB J, 10: 940–954.


  1. Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, et al., 2021, The role of the ATP-binding cassette A1 (ABCA1) in human disease. Int J Mol Sci, 22(4): 1593.


  1. Inoue M, Tanabe H, Nakashima K, et al., 2014, Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid Bexarotene. J Nat Prod, 77(7): 1670–1677.


  1. Bowen CM, Walter L, Borras E, et al., 2021 Combination of sulindac and Bexarotene for prevention of intestinal carcinogenesis in familial adenomatous polyposis. Cancer Prev Res (Phila), 14(9): 851–862.


  1. Breneman D, Duvic M, Kuzel T, et al., 2002, Phase 1 and 2 trial of Bexarotene gel for skin-directed treatments of patients with cutaneous t-cell lymphoma. Arch Dermatol, 138(3): 325–333.


  1. Shen D, Yu X, Wu Y, et al., 2018, Emerging roles of Bexarotene in the prevention, treatment and anti-drug resistance of cancers. Expert Rev Anticancer Ther, 18(5): 487–499.


  1. Dummer R, Beyer M, Hymes K, et al., 2012, Vorinostat combined with Bexarotene for treatment of cutaneous T-cell lymphoma: In vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma, 53(8): 1501–1508.


  1. Butler RM, McKenzie RC, Jones CL, et al., 2019, Contribution of stat3 and rad23b in primary sézary cells to histone deacetylase inhibitor FK228 resistance. J Invest Dermatol, 139(9): 1975–1984.e2.


  1. Budgin JB, Richardson SK, Newton SB, et al., 2015, Biological effects of Bexarotene in cutaneous T-cell lymphoma. Arch Dermatol, 141(3): 315–321.


  1. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al., 2004, Low-dose oral Bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: Clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol, 50(3): 375–409.


  1. Singh F, Lebwohl MG, 2004, Cutaneous T-cell lymphoma treatment using Bexarotene and PUVA: A case series. J Am Acad Dermatol, 51(4): 570–573.


  1. Morita A, Tateishi C, Muramatsu S, et al., 2020, Efficacy and safety of Bexarotene combined with photo (chemo) therapy for cutaneous T-cell lymphoma. J Dermatol, 47(5):443–451.


  1. Straus DJ, Duvic M, Kuzel T, et al., 2007, Results of a phase II trial of oral Bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer, 109(9): 1799–1803.


  1. Wang Y, Rong J, Zhang J, et al., 2007, Morphology, in vivo distribution and antitumor activity of Bexarotene nanocrystals in lung cancer. Drug Dev Ind Pharm, 43(1): 132–141.


  1. Hermann TW, Yen WC, Tooker P, et al., 2005, The retinoid X receptor agonist Bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer, 50(1): 9–18.


  1. Dragnev KH, Whyman JD, Hahn CK, et al., 2018, A phase I/II study of Bexarotene with Carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer. J Thorac Dis, 10(9): 5531–5537.


  1. Padda SK, Chhatwani L, Zhou L, et al., 2013, Phase I and pharmacokinetic study of Bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: Brief report. Anticancer Drugs, 24(7): 731–735.


  1. Ai X, Mao F, Shen S, et al., 2018, Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/ PPARγ/PTEN/mTOR signaling pathway. BMC Cancer, 18(1): 407.


  1. Esteva FJ, Valero V, Pusztai L, et al., 2001, Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist, 6: 133–146.


  1. Welsch CW, 1985, Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res, 45: 3415–3443.


  1. Gottardis MM, Jordan VC, 1987, Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res, 47: 4020–4024.


  1. Yen WC, Lamph WW, 2005, The selective retinoid X receptor agonist Bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther, 4(5): 824–834.


  1. Kong JN, He Q, Wang G, et al., 2015, Guggulsterone and Bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells. Int J Cancer, 137(7): 1610–1620.


  1. Kong G, Kim HT, Wu K, et al., 2005, The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: Implications for molecular-based chemoprevention. Cancer Res, 65(8): 3462–3469.


  1. Disis ML, Gad E, Herendeen DR, et al., 2013, A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila), 6(12): 1273–1282.


  1. Ying SX, Seal S, Abbassi N, et al., 2007, Differential effects of Bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma, 48(5): 1003–1014.


  1. Klopper JP, Berenz A, Hays WR, et al., 2008, In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res, 14(2): 589–596.


  1. Liu YY, 2006, Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol, 154(4): 525–531.


  1. Saito-Hakoda A, Uruno A, Yokoyama A, et al., 2015, Effects of RXR agonists on cell proliferation/apoptosis and ACTH secretion/POMC expression. PLoS One, 10(12): e0141960.
  2. Castillo V, Giacomini D, Páez-Pereda M, et al., 2006, Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology, 147(9): 4438–4444.


  1. Atmaca H, Islek I, Senturk N, 2013, Reversible pituitary insufficiency due to Bexarotene therapy in a patient with mycosis fungoides. Pituitary, 17(5): 492–493.


  1. Yu H, Ren S, Wang J, et al., 2020, Bexarotene combined with Lapatinib for the treatment of Cushing’s disease: Evidence based on drug repositioning and experimental confirmation. Signal Transduct Target Ther, 5(1): 175.


  1. Talpur R, Vu J, Bassett R, et al., 2019, Phase I/II randomized bilateral half-head comparison of topical Bexarotene 1% gel for alopecia areata. J Am Acad Dermatol, 61: 592–598.e1-9.


  1. Dong H, Wang H, Wang L, 2020, Inhibition of MAPT enhances the effect of Bexarotene and attenuates the damage after traumatic brain injury using in vivo and in vitro experiments. Folia Neuropathol, 58(3): 253–264.


  1. Chang CF, Massey J, Osherov A, et al., 2020, Bexarotene enhances macrophage erythrophagocytosis and hematoma clearance in experimental intracerebral hemorrhage. Stroke, 51: 612–618.


  1. Tu L, Yang XL, Zhang Q, et al., 2018, Bexarotene attenuates early brain injury via inhibiting micoglia activation through PPARγ after experimental subarachnoid hemorrhage. Neurol Res, 40(8): 702–708.


  1. Yuan C, Dai C, Li Z, et al., 2020, Bexarotene improve depression-like behaviour in mice by protecting against neuro-inflammation and synaptic damage. Neurochem Res, 45(7): 1500–1509.


  1. Mahajan A, Kaur L, Singh G, et al., 2022, COVID19 vaccines: Fabrication techniques and current status. Coronaviruses, 3(1): 42–48.


  1. Yuan S, Chan JFW, Chik KKH, et al., 2020, Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol Res, 159: 104960.


  1. Shahabadi N, Zendehcheshm S, Mahdavi M, et al., 2021, Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. Inform Med Unlocked, 26: 100745.


  1. Kobayashi T, Mitsuhashi A, Hongying P, et al., 2022, Bexaroteneinduced cell death in ovarian cancer cells through Caspase4gasdermin E mediated pyroptosis. Sci Rep, 12: 11123.


  1. Hurst RE, 2000, Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs, 1(4): 514–523.


  1. FDA Approves Ligand’s Targretin Gel, 2023. Available from: [Last accessed on 2023 Aug 01].


  1. Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe, 2023. Available from: news/news201212.html [Last accessed on 2023 Aug 01].


  1. Saka R, Jain H, Kommineni N, et al., 2020, Enhanced penetration and improved therapeutic efficacy of Bexarotene via topical liposomal gel in imiquimod induced 16 psoriatic plaque model in BALB/c mice. J Drug Deliv Sci Technol, 58: 101691.


  1. de Oliveira ER Jr., Santos LCR, Salomão MA, et al., 2020, Nose-to-brain drug delivery mediated by polymeric nanoparticles: Influence of PEG surface coating. Drug Deliv Transl Res, 10(6): 1688–1699.


  1. Zhang Q, Lee SB, Chen X, et al., 2019, Optimized Bexarotene aerosol formulation inhibits major subtypes of lung cancer in mice. Nano Lett, 19: 2231−2242.


  1. Vasile A, Ignat M, Zaltariov MF, et al., 2018, Development of new Bexarotene-loaded mesoporous silica systems for topical pharmaceutical formulations. Acta Chim Slov, 65(1): 97–107.


  1. Lee JB, Kim TH, Feng W, et al., 2019, Quantitative prediction of oral bioavailability of a lipophilic antineoplastic drug bexarotene administered in lipidic formulation using a combined in vitro lipolysis/microsomal metabolism approach. J Pharm Sci, 108(2): 1047–1052.


  1. Singh L, Kaur L, Singh G, et al., 2022, Determination of alteration in micromeritic properties of a solid dispersion: Brunauer-Emmett-Teller based adsorption and other structured approaches. AAPS PharmSciTech, 23(6): 209.


  1. Xiao F, Cheng Y, Wang JR, et al., 2022, Cocrystal prediction of bexarotene by graph convolution network and bioavailability improvement. Pharmaceutics, 14(10): 2198.


  1. Kryczyk-Poprawa A, Zupkó I, Bérdi P, et al., 2021, Photodegradation of Bexarotene and its implication for cytotoxicity. Pharmaceutics, 13(8): 1220.


  1. Toi N, Kurajoh M, Miyaoka D, et al., 2022, Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. Endocr J, 69(1): 101–105.


  1. Makita N, Manaka K, Sato J, et al., 2019, Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies. Clin Endocrinol (Oxf), 91(1): 195–200.


  1. Chiang ACA, Seua AV, Singhmar P, et al., 2020, Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun, 8: 193.


  1. Hacioglu C, Kar F, Kacar S, et al., 2021, Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARγ/NF-κB signaling pathway in C6 glioma cells. Med Oncol, 38(3): 31.


  1. Ning Z, 2008, CN100434068C, Bexarotene Gel and its Preparation Method.


  1. Jinhui ZN, 2013, CN103181912A, Bexarotene Soft Capsules and Preparation Method Thereof.


  1. Willers C, 2013, EP2612665A1, Topical Pharmaceutical Compositions Comprising Bexarotene and a Corticosteroide.


  1. Lijiang C, 2018, CN104922062A, Bexarotene Nano Suspension.


  1. Liu B, 2019, US20190038566A1, Bexarotene Soft Gel Capsule and Preparation Method Thereof.


  1. Yang L, 2020, CN111718257A, Bexarotene and Ligustrazine Eutectic Compound, Preparation Method, Composition and Application Thereof.


  1. Wei L, 2005, CN1205166C, Synthesis of Antitumour Medicine Bexarotene.


  1. Bhirud SB, 2011, WO2011141928A1, Process for the Preparation of Highly Pure Bexarotene.


  1. Wagner CE, 2015, US9174917B2, Bexarotene Analogs.
Conflict of interest
The authors declare no conflict of interest.
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing